ROIV News and Press, Roivant Sciences Ltd. From 03/03/26

FDA assigns PDUFA target action date in the third quarter of calendar year 2026 with launch expected at the end of September 2026 Priority Review supported by positive Phase 3 VALOR results, the first positive 52-week placebo-controlled trial in dermatomyositis If approved, brepocitinib would r...

2026-02-09 08:15:05 ET Jefferies analyst issues BUY recommendation for ROIV on February 9, 2026 01:22PM ET. The previous analyst recommendation was Buy. ROIV was trading at $25.82 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...

2026-02-06 22:37:02 ET Overview Roivant’s ( ROIV ) stock is up 18% this morning after its subsidiary, Priovant Therapeutics, reported Phase 2 BEACON data in cutaneous sarcoidosis. Bear in mind that Roivant owns ~74% of Priovant–with Pfizer ( PFE ) nearly ow...

2026-02-06 15:46:12 ET More on Roivant Sciences Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call Transcript Roivant Sciences Ltd. 2025 Q3 - Results - Earnings Call Presentation Roivant Sciences: King Of The Vants Prepares To Drop Vantism In Search Of Greater Growth...

2026-02-06 15:44:20 ET Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call February 6, 2026 8:00 AM EST Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms Matthew Gline - CEO & Director Benjamin Zimmer - President of Health...

2026-02-06 09:41:49 ET Denver, Colorado- Markets head into the session with a familiar Super Bowl weekend setup: with investors scanning for near-term catalysts rather than sweeping narratives, today’s action is shaping up as a fundamentals-first matchup. Balance Sheets Get...

2026-02-06 09:02:17 ET More on Pfizer, Roivant Sciences Pfizer Inc. 2025 Q4 - Results - Earnings Call Presentation Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript Pfizer: Messy Q4 Earnings Mask An Improving Business Pfizer wins FDA priority review for Hymp...

2026-02-06 07:07:16 ET More on Roivant Sciences Roivant Sciences: King Of The Vants Prepares To Drop Vantism In Search Of Greater Growth Roivant Sciences Ltd. (ROIV) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Roivant Sciences Ltd. (ROIV) Pr...

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ 21.6 P<0.0001) All brepocitinib 45 mg patients achieved a clinically meaningful response, with 10...

PHocus enrollment completed in under 12 months from first patient dosed, representing a rapid enrollment pace in pulmonary hypertension associated with interstitial lung disease Topline results on track for second half of calendar year 2026 WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Pu...